DANISH BIO – DANSK BIOTEK organizes four major plenary meetings for our members throughout the year to increase our members' knowledge regarding specific biotech topics and to facilitate networking. The events usually take place in February, May, September and November.

We also organize approximately four "saloon" meetings annually. They are small, intimate, "meet the expert" meetings with typically 6-20 participants advocating more in-depth discussion and knowledge-sharing on specific themes.

News

MinervaX announces 72M EUR financing to advance development of novel vaccine against Group B Streptococcus 15 December 2022

Copenhagen, Denmark, 15 December 2022 – MinervaX ApS, a privately held Danish biotechnology company... Read more

<img data-lazyloaded="1" src="data:image/gif;base64,R0lGODdhAQABAPAAAMPDwwAAACwAAAAAAQABAAACAkQBADs=" width="300" height="76" class="logoImg animateRtGeneral" data-src="https://danskbiotek.dk/wp-content/uploads/2021/02/Udklip-4-300x76.jpg" /><noscript><img width="300" height="76" class="logoImg animateRtGeneral" src="https://danskbiotek.dk/wp-content/uploads/2021/02/Udklip-4-300x76.jpg" />

Y-mAbs Announces Pipeline Update 14 December 2022

NEW YORK, Dec. 14, 2022 (GLOBE NEWSWIRE) — Y-mAbs Therapeutics, Inc. (the “Company” or... Read more

Y-mAbs’ DANYELZA® (naxitamab-gqgk) for the Treatment of High-Risk Neuroblastoma Approved in China 08 December 2022

NEW YORK, Dec. 08, 2022 (GLOBE NEWSWIRE) — Y-mAbs Therapeutics, Inc. (the “Company” or... Read more

Y-mAbs to Host Annual Research and Development Day in New York 06 December 2022

NEW YORK, Dec. 06, 2022 (GLOBE NEWSWIRE) — Y-mAbs Therapeutics, Inc. (the “Company” or... Read more

<img data-lazyloaded="1" src="data:image/gif;base64,R0lGODdhAQABAPAAAMPDwwAAACwAAAAAAQABAAACAkQBADs=" width="300" height="76" class="logoImg animateRtGeneral" data-src="https://danskbiotek.dk/wp-content/uploads/2021/02/Udklip-4-300x76.jpg" /><noscript><img width="300" height="76" class="logoImg animateRtGeneral" src="https://danskbiotek.dk/wp-content/uploads/2021/02/Udklip-4-300x76.jpg" />

Y-mAbs Announces Complete Response Letter for Omburtamab Biologics License Application 01 December 2022

NEW YORK, Dec. 01, 2022 (GLOBE NEWSWIRE) — Y-mAbs Therapeutics, Inc. (the “Company” or... Read more

New CEO at LINK Medical, the Northern European CRO 21 November 2022

Oslo Norway, November 18, 2022. The LINK Medical Board is pleased to announce the appointment of Sissel... Read more

Development of suPAR tests for commercial use in the US is a post-authorisation reqirement in new EUA of Kineret for COVID-19 10 November 2022

ViroGates announces the emergency use authorisation of Kineret treatment for COVID-19 related pneumonia... Read more

Novo Holdings and Sound Bioventures launch Breye Therapeutics to develop novel oral therapies for ophthalmologic diseases 10 November 2022

COPENHAGEN, Denmark, Nov. 10, 2022 /PRNewswire/ — Breye Therapeutics ApS (Breye), a clinical-stage... Read more

<img data-lazyloaded="1" src="data:image/gif;base64,R0lGODdhAQABAPAAAMPDwwAAACwAAAAAAQABAAACAkQBADs=" width="300" height="76" class="logoImg animateRtGeneral" data-src="https://danskbiotek.dk/wp-content/uploads/2021/02/Udklip-4-300x76.jpg" /><noscript><img width="300" height="76" class="logoImg animateRtGeneral" src="https://danskbiotek.dk/wp-content/uploads/2021/02/Udklip-4-300x76.jpg" />

Y-mAbs Announces Outcome of FDA Advisory Committee Meeting on Omburtamab 28 October 2022

NEW YORK, Oct. 28, 2022 (GLOBE NEWSWIRE) — Y-mAbs Therapeutics, Inc. (the “Company” or... Read more

Copyright 2022 DANISH BIO – DANSK BIOTEK. All rights reserved.

created by: Mastafu Design